• Study Comparing CPX-351 and Chemotherapy for Patients with New Intermediate or High-Risk Acute Myeloid Leukemia

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study on Abatacept for Rheumatoid Arthritis in Patients Responding to Initial TNF Inhibitor Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study on Nalmefene and Placebo for Reducing Cravings in Patients with Gambling Disorder, Sexual Addiction, or Food Addiction

    Recruiting

    3 1 1
    Investigated Diseases:
    France

  • Study on the Safety and Effects of ACI-24.060 for Patients with Early Alzheimer’s Disease and Adults with Down Syndrome

    Recruiting

    1 1 1
    Investigated Drugs:
    Spain

  • Study on UCPVax, Atezolizumab, and Bevacizumab for Patients with Unresectable Liver Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    France

  • Study on the Effectiveness of Dutasteride with Goserelin Acetate and Bicalutamide in Patients with Recurrent or Metastatic Salivary Duct Carcinoma

    Recruiting

    4 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands

  • Study on How Degarelix and Drug Combination Affect Gut Health in Patients with Prostate Cancer or Benign Prostate Hyperplasia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Finland

  • Study of Nivolumab, Cisplatin, and 5-Fluorouracil for Children and Adults with EBV-Positive Nasopharyngeal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Study on Colchicine for Reducing Atrial Fibrillation Recurrence in Patients Undergoing Electrical Cardioversion

    Recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Denmark

  • Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

    Recruiting

    3 1 1
    Investigated Drugs:
    Austria Croatia Czechia Denmark France Germany +3

powered by